论文部分内容阅读
目的观察前列地尔联合非诺贝特对高脂血症性重症胰腺炎的治疗效果。方法将35例HSAP患者随机分为对照组(17例)和治疗组(18例)。对照组给予常规治疗,治疗组在对照组治疗方案基础上给予静脉滴注前列地尔及口服非诺贝特治疗,14d为1疗程。对两组疗效进行比较。结果治疗组在临床症状/体征缓解时间、首疗程总有效率、并发症发生率及死亡率等方面均优于对照组。结论前列地尔联合非诺贝特治疗HSAP疗效可靠、安全,可作为HSAP常规治疗的有益选择。
Objective To observe the therapeutic effect of alprostadil combined with fenofibrate on hyperlipidemic severe acute pancreatitis. Methods 35 patients with HSAP were randomly divided into control group (17 cases) and treatment group (18 cases). The control group was given routine treatment. The treatment group was given intravenous infusion of alprostadil and oral fenofibrate on the basis of the control group. The course of treatment was 14 days. The efficacy of the two groups were compared. Results The treatment group was superior to the control group in clinical symptom / symptom relief time, total effective rate of the first course of treatment, complication rate and mortality. Conclusions The combination of alprostadil and fenofibrate in the treatment of HSAP is reliable and safe and can be a good choice for routine HSAP treatment.